Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Long-Term Use of Antithyroid Drugs
source: Graves’ Disease & Thyroid Foundation (GDATF)
year: 2021
summary/abstract:Antithyroid medications (ATDs) have been prescribed for decades as a treatment option for hyperthyroidism in Graves’ disease patients. The U.S. Food and Drug Administration approved propylthiouracil in 1947 and methimazole (brand name Tapazole) in 1950.
In the past, endocrinologists typically prescribed ATDs for a limited period of time. Some doctors used 12-18 months as a benchmark, while others would keep patients on the medication for up to two years. Once the clock ran out, doctors stopped the medication and checked the patient’s thyroid function. If levels were in the normal range, the treatment was declared a success. If thyroid levels were still not well controlled (or if the patient became hyperthyroid again after stopping the medication) doctors would recommend radioactive iodine or surgery, which are definitive therapies that result in life-long hypothyroidism.
However, a paradigm shift in recent years – ushered in by new research as well as patient and physician preference – has brought changes to how these medications are used, with more patients remaining on antithyroid medications well past the two-year mark.
read more
myBinderRelated Content
-
Post-Partum and Non-Post-Partum Relapsing Graves’ Hyperthyroidism Display Different Response to Anti-Thyroid D...Design: Graves’ disease (GD) patients...
-
Maria Albuja-Cruz, MDMaria Albuja-Cruz is an Associate Profes...
-
Effects of Selenium on Short-Term Control of Hyperthyroidism due to Graves’ Disease Treated With Methimazole: ...Objective: In spite of previous conflic...
-
How Vanessa Vanderstraaten Copes With the Disease, HyperthyroidismOn the surface, everything appears to be...
-
Drug Effects on the ThyroidThe list of medications, many commonly u...
-
Thyroid Eye Disease Drug Meets Primary Endpoint for Proptosis ReductionTop-line results from the OPTIC trial sh...
-
Selenium in Graves Hyperthyroidism and OrbitopathyPurpose: To review the in vitro and in ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Google